Complement inhibitors for age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Williams, Michael A ^a   Mckay, Gareth J ^b   Chakravarthy, Usha ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR;

AGE RELATED MACULAR DEGENERATION; BEST CORRECTED VISUAL ACUITY; BLINDNESS; CONTRAST SENSITIVITY; DRUG EFFECT; DRUG SAFETY; ENDOPHTHALMITIS; FOLLOW UP; HUMAN; HYPERTENSION; INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINAL THICKNESS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UVEITIS; VISION; IMMUNOLOGY; RETINA MACULA DEGENERATION;

COMPLEMENT INACTIVATING AGENTS; HUMANS; MACULAR DEGENERATION;

EID: 84903195088     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009300.pub2     Document Type: Review

References (51)

1. NCT00935883 Eculizumab for the treatment of non-exudative age-related macular degeneration: an exploratory study to evaluate the effects of C5 inhibition on drusen and geographic atrophy. clinicaltrials.gov/show/NCT00935883 (accessed 28 May 2013).
2. NCT00950638 A phase I study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. clinicaltrials.gov/show/Nct00950638 (accessed 28 May 2013).
3. Anonymous Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration. Nature Reviews Drug Discovery 2009;8:922.
4. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology 2001;119(10):1417-36.
5. Augood CA, Vingerling JR, De Jong PT, Chakravarthy U, Seland J, Soubrane G, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Archives of Ophthalmology 2006;124(4):529-35.
6. Bora PS, Sohn JH, Cruz JM, Jha P, Nishihori H, Wang Y, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. Journal of Immunology 2005;174(1):491-7.
7. Büttner-Mainik A, Parsons J, Jérôme H, Hartmann A, Lamer S, Schaaf A, et al. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnology Journal 2011;9(3):373-83.
8. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010;10:31.
9. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002;99(23):14682-7.
10. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
11. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, De Maat MP, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296(3):301-9.
12. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308(5720):421-4.
13. Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology 2004;111(3):513-7.
14. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
15. Hageman GS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Progress in Retinal and Eye Research 2001;20(6):705-32.
16. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2005;102(20):7227-32.
17. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308(5720):419-21.
18. Haines JL, Spencer KM, Pericak-Vance MA. Bringing the genetics of macular degeneration into focus. Proceedings of the National Academy of Sciences of the United States of America 2007;104(43):16725-6.
19. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. Journal of Neuroimmunology 2007;184(1-2):69-91.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
21. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
22. Hogg RE, Stevenson MR, Chakravarthy U, Beirne RO, Anderson RS. Early features of AMD. Ophthalmology 2007;114(5):1028.
23. Issa CP, Chong NV, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefe's Archive for Clinical and Experimental Ophthalmology 2011;249(2):163-74.
24. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Experimental Eye Research 2000;70(4):441-9.
25. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11830-5.
26. Khandhadia S, Cipriani V, Yates JR, Lotery AJ. Age-related macular degeneration and the complement system. Immunobiology 2012;217(2):127-46.
27. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:365.
28. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308(5720):385-9.
29. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. American Journal of Pathology 2007;171(3):715-27.
30. Safety of intravitreal POT-4 therapy for patients with neovascular age-related macular degeneration. ClinicalTrials.gov/show/NCT00473928 (accessed 28 May 2013).
31. ARC1905 (ANTI-C5 APTAMER) given either in combination therapy with Lucentis® 0.5 mg/eye in subjects with neovascular age-related macular degeneration. ClinicalTrials.gov/show/NCT00709527 (accessed 28 May 2013).
32. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. British Journal of Ophthalmology 2003;87(3):312-7.
33. Patel N, Adewoyin T, Chong NV. Age-related macular degeneration: a perspective on genetic studies. Eye 2008;22(6):768-76.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
35. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nature Biotechnology 2007;25(11):1265-75.
36. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:594.
37. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Molecular Immunology 2004;41(4):355-67.
38. Schwartz SG, Brantley MA, Jr Pharmacogenetics and age-related macular degeneration. Journal of Ophthalmology 2011:Article ID 252549. [DOI: 10.1155/2011/252549]
39. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. American Journal of Ophthalmology 1997;124(2):199-206.
40. Sivaprasad S, Chong NV. The complement system and age-related macular degeneration. Eye 2006;20(8):867-72.
41. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
42. Tamamis P, López de Victoria A, Gorham RD Jr, Bellows-Peterson ML, Pierou P, Floudas CA, et al. Molecular dynamics in drug design: new generations of compstatin analogs. Chemical Biology and Drug Design 2012;79(5):703-18.
43. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 2005;19(9):935-44.
44. Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clinical and Experimental Ophthalmology 2012;40(1):18-26.
45. www.alexionpharm.com/.
46. www.archemix.com/website/index.php.
47. UPstart at the University of Pennsylvania. www.ctt.upenn.edu/upstart.html (accessed 24 May 2012).
48. www.jerini.com/cms/en/home.php.
49. www.ophthotech.com/.
50. www.potentiapharma.com/about/news.htm (accessed 13 May 2012).
51. Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular degeneration. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD009300]